ACTION: Notice of hearing.

SUMMARY: This notice announces an administrative hearing on June 14, 1995, at 10 a.m. in the 15th Floor Conference Room, 105 West Adams, Chicago, Illinois to reconsider our decision to disapprove Illinois SPA 93–14.

CLOSING DATE: Requests to participate in the hearing as a party must be received by the presiding officer by May 19, 1995.

FOR FURTHER INFORMATION CONTACT: Stan Katz, Presiding Officer, Ground floor, Meadowwood East Building, 1849 Gwynn Oak Avenue, Baltimore, Maryland 21207, Telephone: (410) 597–3013.

SUPPLEMENTARY INFORMATION: This notice announces an administrative hearing to reconsider our decision to disapprove Illinois State plan amendment (SPA) number 93–14.

Section 1116 of the Social Security Act (the Act) and 42 CFR part 430 establish Department procedures that provide an administrative hearing for reconsideration of a disapproval of a State plan or plan amendment. The Health Care Financing Administration (HCFA) is required to publish a copy of the notice to a State Medicaid agency that informs the agency of the time and place of the hearing and the issues to be considered. If we subsequently notify the agency of additional issues that will be considered at the hearing, we will also publish that notice.

Any individual or group that wants to participate in the hearing as a party must petition the presiding officer within 15 days after publication of this notice, in accordance with the requirements contained at 42 CFR 430.76(b)(2). Any interested person or organization that wants to participate as amicus curiae must petition the presiding officer before the hearing begins in accordance with the requirements contained at 42 CFR 430.76(c). If the hearing is later rescheduled, the presiding officer will notify all participants.

The State of Illinois submitted SPA 93–14 on October 18, 1994, to establish a new payment adjustment for uncompensated care services, and requested an effective date of July 1, 1993.

The issue in this matter is whether Illinois SPA 93–14, meets Federal regulations which require the State to comply with the public notice requirements in Section 447.205.

Illinois published public notice on August 6, 1993, with the plan amendment's proposed effective date of July 1, 1993.

HCFA believes the proposed effective date of the plan amendment was not approvable because the State failed to comply with the Federal regulation at 42 CFR 447.253(h) which requires that the Medicaid agency must comply with public notice requirements in § 447.205 when it is proposing significant changes to its methods and standards for setting payment rates for inpatient hospital and long-term care facility services. Section 447.225(d)(1) requires that the notice be published before the proposed effective date of the change. The State's requested effective date is prior to the date of the public notice announcement.

However, because public notice was published on August 5, 1993, HCFA believes the plan amendment was approvable with an effective date of August 6, 1993.

The State of Illinois contends that the change was not significant.

Additionally, Illinois challenges HCFA's disapproval because public notice was published prior to the State's implementation of the amendment, and because the eventual disallowances of Federal financial participation funds based on public notice requirements are the subject of current regulatory reform proposals.

Under HCFA's policy, the sole factor in determining a significant change is the degree to which the State is proposing to modify its payment methods and standards. HCFA believes since this amendment established a new payment adjustment for uncompensated care services, the amendment represents a significant change in the methods and standards used to determine payment rates.

The notice to Illinois announcing an administrative hearing to reconsider the disapproval of its SPA reads as follows:

Mr. Robert W. Wright,

Director, Illinois Department of Public Aid, Jesse B. Harris Building II, 3rd Floor, 100 South Grand Avenue, East, Springfield, Illinois 62762–0001

Dear Mr. Wright: I am responding to your request for reconsideration of the decision to disapprove Illinois State Plan Amendment (SPA) 93–14. The State of Illinois submitted SPA 93–14 on October 18, 1994, to establish a new payment adjustment for uncompensated care services, and requested an effective date of July 1, 1993.

The issue in this matter is whether Illinois SPA 93–14, meets Federal regulations at 42 CFR 447.253(h) which require the State to comply with the public notice requirements in section 447.205.

I am scheduling a hearing on your request for reconsideration to be held on June 14, 1995, at 10 a.m. in the 15th floor conference room, 105 West Adams, Chicago, Illinois. If this date is not acceptable, we would be glad to set another date that is mutually agreeable to the parties. The hearing will be governed by the procedures prescribed at 42 CFR, Part 430

I am designating Mr. Stanley Katz as the presiding officer. If these arrangements present any problems, please contact the presiding officer. In order to facilitate any communication which may be necessary between the parties to the hearing, please notify the presiding officer to indicate acceptability of the hearing date that has been scheduled and provide the names of the individuals who will represent the State at the hearing. The presiding officer may be reached at (410) 597–3013.

Sincerely,

Bruce C. Vladeck, *Administrator.*

(Sec. 1116 of the Social Security Act (42 U.S.C. section 1316); 42 CFR 430.18) (Catalog of Federal Domestic Assistance Program No. 13.714, Medicaid Assistance Program)

Dated: April 28, 1995.

Bruce C. Vladeck,

Administrator, Health Care Financing Administration.

[FR Doc. 95–11019 Filed 5–3–95; 8:45 am] BILLING CODE 4120–01–P

Substance Abuse and Mental Health Services Administration

Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies and Laboratories That Have Withdrawn From the Program

AGENCY: Substance Abuse and Mental Health Services Administration, HHS, (Formerly: National Institute on Drug Abuse, ADAMHA, HHS).

ACTION: Notice.

SUMMARY: The Department of Health and **Human Services notifies Federal** agencies of the laboratories currently certified to meet standards of Subpart C of Mandatory Guidelines for Federal Workplace Drug Testing Programs (59 FR 29916, 29925). A similar notice listing all currently certified laboratories will be published during the first week of each month, and updated to include laboratories which subsequently apply for and complete the certification process. If any listed laboratory's certification is totally suspended or revoked, the laboratory will be omitted from updated lists until such time as it is restored to full certification under the Guidelines.

If any laboratory has withdrawn from the National Laboratory Certification Program during the past month, it will be identified as such at the end of the current list of certified laboratories, and will be omitted from the monthly listing thereafter.

FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh, Division of Workplace Programs, Room 13A–54, 5600 Fishers Lane, Rockville, Maryland 20857; Tel.: (301) 443–6014.

SUPPLEMENTARY INFORMATION:

Mandatory Guidelines for Federal Workplace Drug Testing were developed in accordance with Executive Order 12564 and section 503 of Pub. L. 100-71. Subpart C of the Guidelines, "Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies," sets strict standards which laboratories must meet in order to conduct urine drug testing for Federal agencies. To become certified an applicant laboratory must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification a laboratory must participate in a quarterly performance testing program plus periodic, on-site inspections.

Laboratories which claim to be in the applicant stage of certification are *not* to be considered as meeting the minimum requirements expressed in the HHS Guidelines. A laboratory must have its letter of certification from SAMHSA, HHS (formerly: HHS/NIDA) which attests that it has met minimum standards.

In accordance with Subpart C of the Guidelines, the following laboratories meet the minimum standards set forth in the Guidelines:

- ACCU-LAB, Inc., 405 Alderson St., Schofield, WI 54476, 800–627–8200 (formerly: Alpha Medical Laboratory, Inc., Employee Health Assurance Group, ExpressLab, Inc.)
- Aegis Analytical Laboratories, Inc., 624 Grassmere Park Rd., Suite 21, Nashville, TN 37211, 615–331–5300
- Alabama Reference Laboratories, Inc., 543 South Hull St., Montgomery, AL 36103, 800–541–4931/205–263–5745
- American Medical Laboratories, Inc., 14225 Newbrook Dr., Chantilly, VA 22021, 703–802–6900
- Associated Pathologists Laboratories, Inc., 4230 South Burnham Ave., Suite 250, Las Vegas, NV 89119–5412, 702– 733–7866
- Associated Regional and University Pathologists, Inc. (ARUP), 500 Chipeta Way, Salt Lake City, UT 84108, 801– 583–2787
- Baptist Medical Center—Toxicology Laboratory, 9601 I–630, Exit 7, Little Rock, AR 72205–7299, 501–227–2783 (formerly: Forensic Toxicology Laboratory Baptist Medical Center)
- Bayshore Clinical Laboratory, 4555 W. Schroeder Dr., Brown Deer, WI 53223, 414–355–4444/800–877–7016

- Cedars Medical Center, Department of Pathology, 1400 Northwest 12th Ave., Miami, FL 33136, 305–325–5810
- Centinela Hospital Airport Toxicology Laboratory, 9601 S. Sepulveda Blvd., Los Angeles, CA 90045, 310–215– 6020
- Clinical Reference Lab, 11850 West 85th St., Lenexa, KS 66214, 800–445–6917
- CORNING Clinical Laboratories, South Central Divison, 2320 Schuetz Rd., St. Louis, MO 63146, 800–288–7293 (formerly: Metropolitan Reference Laboratories, Inc.)
- CORNING Clinical Laboratories, 8300 Esters Blvd., Suite 900, Irving, TX 75063, 800–526–0947 (formerly: Damon Clinical Laboratories, Damon/ MetPath)
- CORNING MetPath Clinical Laboratories, 1355 Mittel Blvd., Wood Dale, IL 60191, 708–595–3888 (formerly: MetPath, Inc.)
- CORNING MetPath Clinical Laboratories, One Malcolm Ave., Teterboro, NJ 07608, 201–393–5000 (formerly: MetPath, Inc.)
- CORNING National Center for Forensic Science, 1901 Sulphur Spring Rd., Baltimore, MD 21227, 410–536–1485 (formerly: Maryland Medical Laboratory, Inc., National Center for Forensic Science)
- CORNING Nichols Institute, 7470–A Mission Valley Rd., San Diego, CA 92108–4406, 800–446–4728/619–686– 3200 (formerly: Nichols Institute, Nichols Institute Substance Abuse Testing (NISAT))
- Cox Medical Centers, Department of Toxicology, 1423 North Jefferson Ave., Springfield, MO 65802, 800– 876–3652/417–836–3093
- Dept. of the Navy, Navy Drug Screening Laboratory, Great Lakes, IL, Building 38–H, Great Lakes, IL 60088–5223, 708–688–2045/708–688–4171
- Diagnostic Services Inc., dba DSI, 4048 Evans Ave., Suite 301, Fort Myers, FL 33901, 813–936–5446/800–735–5416
- Doctors Laboratory, Inc., P.O. Box 2658, 2906 Julia Dr., Valdosta, GA 31604, 912–244–4468
- Drug Labs of Texas, 15201 I–10 East, Suite 125, Channelview, TX 77530, 713–457–3784
- DrugProof, Division of Dynacare/ Laboratory of Pathology, LLC, 1229 Madison St., Suite 500, Nordstrom Medical Tower, Seattle, WA 98104, 800–898–0180 / 206–386–2672 (formerly: Laboratory of Pathology of Seattle, Inc., DrugProof, Division of Laboratory of Pathology of Seattle, Inc.)
- DrugScan, Inc., P.O. Box 2969, 1119Mearns Rd., Warminster, PA 18974, 215–674–9310

- Eagle Forensic Laboratory, Inc., 950 N. Federal Highway, Suite 308, Pompano Beach, FL 33062, 305–946–4324
- ElSohly Laboratories, Inc., 5 Industrial Park Dr., Oxford, MS 38655, 601–236– 2609
- General Medical Laboratories, 36 South Brooks St., Madison, WI 53715, 608– 267–6267
- Harrison Laboratories, Inc., 9930 W. Highway 80, Midland, TX 79706, 800–725–3784/915–563–3300 (formerly: Harrison & Associates Forensic Laboratories)
- HealthCare/MetPath, 24451 Telegraph Rd., Southfield, MI 48034, 800–444– 0106 ext. 650 (formerly: HealthCare/ Preferred Laboratories)
- Holmes Regional Medical Center Toxicology Laboratory, 5200 Babcock St., N.E., Suite 107, Palm Bay, FL 32905, 407–726–9920
- Jewish Hospital of Cincinnati, Inc., 3200 Burnet Ave., Cincinnati, OH 45229, 513–569–2051
- LabOne, Inc., 8915 Lenexa Dr., Overland Park, Kansas 66214, 913–888–3927 (formerly: Center for Laboratory Services, a Division of LabOne, Inc.)
- Laboratory Specialists, Inc., 113 Jarrell Dr., Belle Chasse, LA 70037, 504– 392–7961
- Marshfield Laboratories, 1000 North Oak Ave., Marshfield, WI 54449, 715– 389–3734/800–222–5835
- MedExpress/National Laboratory Center, 4022 Willow Lake Blvd., Memphis, TN 38175, 901–795–1515
- Medical College Hospitals Toxicology Laboratory, Department of Pathology, 3000 Arlington Ave., Toledo, OH 43699–0008, 419–381–5213
- Medlab Clinical Testing, Inc., 212 Cherry Lane, New Castle, DE 19720, 302–655–5227
- MedTox Laboratories, Inc., 402 W. County Rd. D, St. Paul, MN 55112, 800–832–3244/612–636–7466
- Methodist Hospital of Indiana, Inc., Department of Pathology and Laboratory Medicine, 1701 N. Senate Blvd., Indianapolis, IN 46202, 317– 929–3587
- Methodist Medical Center Toxicology Laboratory, 221 N.E. Glen Oak Ave., Peoria, IL 61636, 800–752–1835/309– 671–5199
- MetPath Laboratories, 875 Greentree Rd., 4 Parkway Ctr., Pittsburgh, PA 15220–3610, 412–931–7200 (formerly: Med-Chek Laboratories, Inc., Med-Chek/Damon)
- MetroLab-Legacy Laboratory Services, 235 N. Graham St., Portland, OR 97227, 503–413–4512, 800–237–7808 (x4512)
- National Health Laboratories Incorporated, 2540 Empire Dr., Winston-Salem, NC 27103–6710,

- Outside NC: 919–760–4620/800–334–8627 / Inside NC: 800–642–0894
- National Health Laboratories Incorporated, d.b.a. National Reference Laboratory, Substance Abuse Division, 1400 Donelson Pike, Suite A–15, Nashville, TN 37217, 615–360–3992/800–800–4522
- National Health Laboratories Incorporated, 13900 Park Center Rd., Herndon, VA 22071, 703–742–3100
- National Psychopharmacology Laboratory, Inc., 9320 Park W. Blvd., Knoxville, TN 37923, 800–251–9492
- National Toxicology Laboratories, Inc., 1100 California Ave., Bakersfield, CA 93304, 805–322–4250
- Northwest Toxicology, Inc., 1141 E. 3900 South, Salt Lake City, UT 84124, 800–322–3361
- Oregon Medical Laboratories, P.O. Box 972, 722 East 11th Ave., Eugene, OR 97440–0972, 503–687–2134
- Pathology Associates Medical Laboratories, East 11604 Indiana, Spokane, WA 99206, 509–926–2400
- PDĹA, Inc. (Princeton), 100 Corporate Court, So. Plainfield, NJ 07080, 908– 769–8500/800–237–7352
- PharmChem Laboratories, Inc., 1505–A O'Brien Dr., Menlo Park, CA 94025, 415–328–6200/800–446–5177
- PharmChem Laboratories, Inc., Texas Division, 7606 Pebble Dr., Fort Worth, TX 76118, 817–595–0294 (formerly: Harris Medical Laboratory)
- Physicians Reference Laboratory, 7800 West 110th St., Overland Park, KS 66210, 913–338–4070/800–821–3627 (formerly: Physicians Reference Laboratory Toxicology Laboratory)
- Poisonlab, Inc., 7272 Clairemont Mesa Rd., San Diego, CA 92111, 619–279– 2600/800–882–7272
- Puckett Laboratory, 4200 Mamie St., Hattiesburgh, MS 39402, 601–264– 3856/800–844–8378
- Regional Toxicology Services, 15305 N.E. 40th St., Redmond, WA 98052, 206–882–3400
- Roche Biomedical Laboratories, Inc., 1120 Stateline Rd., Southaven, MS 38671, 601–342–1286
- Roche Biomedical Laboratories, Inc., 69 First Ave., Raritan, NJ 08869, 800– 437–4986
- Roche CompuChem Laboratories, Inc., A Member of the Roche Group, 3308 Chapel Hill/Nelson Hwy., Research Triangle Park, NC 27709, 919–549– 8263/800–833–3984 (Formerly: CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical Laboratory)
- Roche CompuChem Laboratories, Inc., Special Division, A Member of the Roche Group, 3308 Chapel Hill/ Nelson Hwy., Research Triangle Park, NC 27709, 919–549–8263 (Formerly:

- CompuChem Laboratories, Inc.— Special Division)
- Scientific Testing Laboratories, Inc., 463 Southlake Blvd., Richmond, VA 23236, 804–378–9130
- Scott & White Drug Testing Laboratory, 600 S. 25th St., Temple, TX 76504, 800–749–3788
- S.E.D. Medical Laboratories, 500 Walter NE, Suite 500, Albuquerque, NM 87102, 505–848–8800
- Sierra Nevada Laboratories, Inc. 888 Willow St. Reno, NV 89502 800–648– 5472
- SmithKline Beecham Clinical Laboratories, 7600 Tyrone Ave., Van Nuys, CA 91045, 818–376–2520
- SmithKline Beecham Clinical Laboratories, 801 East Dixie Ave., Leesburg, FL 34748, 904–787–9006 (formerly: Doctors & Physicians Laboratory)
- SmithKline Beecham Clinical Laboratories, 3175 Presidential Dr., Atlanta, GA 30340, 404–934–9205 (formerly: SmithKline Bio-Science Laboratories)
- SmithKline Beecham Clinical Laboratories, 506 E. State Pkwy., Schaumburg, IL 60173, 708–885–2010 (formerly: International Toxicology Laboratories)
- SmithKline Beecham Clinical Laboratories, 400 Egypt Rd., Norristown, PA 19403, 800–523–5447 (formerly: SmithKline Bio-Science Laboratories)
- SmithKline Beecham Clinical Laboratories, 8000 Sovereign Row, Dallas, TX 75247, 214–638–1301 (formerly: SmithKline Bio-Science Laboratories)
- South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South Bend, IN 46601, 219–234–4176
- Southwest Laboratories, 2727 W. Baseline Rd., Suite 6, Tempe, AZ 85283, 602–438–8507
- St. Anthony Hospital (Toxicology Laboratory), P.O. Box 205, 1000 N. Lee St., Oklahoma City, OK 73102, 405–272–7052
- Toxicology & Drug Monitoring Laboratory, University of Missouri Hospital & Clinics, 301 Business Loop 70 West, Suite 208, Columbia, MO 65203, 314–882–1273
- Toxicology Testing Service, Inc., 5426 N.W. 79th Ave., Miami, FL 33166, 305–593–2260
- TOXWORX Laboratories, Inc., 6160 Variel Ave., Woodland Hills, CA 91367, 818–226–4373 (formerly: Laboratory Specialists, Inc.; Abused Drug Laboratories; MedTox Bio-Analytical, a Division of MedTox Laboratories, Inc.)
- UNILAB, 18408 Oxnard St., Tarzana, CA 91356, 800-492-0800/818-343-

8191 (formerly: MetWest-BPL Toxicology Laboratory)

No laboratories withdrew from the Program in April.

Richard Kopanda,

Acting Executive Officer, Substance Abuse and Mental Health Services Administration. [FR Doc. 95–11044 Filed 5–3–95; 8:45 am] BILLING CODE 4160–20–U

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[CA-020-5101-10-B038; CACA-31406, NVN-57250]

Alturas 345 Kilovolt Transmission Line Project; California

AGENCY: Bureau of Land Management, Interior; Susanville District Office, California.

ACTION: Amendment to Notice of Availability of a Draft Environmental Impact Statement (EIS No. 950068).

SUMMARY: The Bureau of Land Management (BLM) and the California **Public Utilities Commission (CPUC)** have prepared a draft Environmental Impact Report/Statement (EIR/S) for the Alturas 345 kilovolt (KV) transmission line project proposed by Sierra Pacific Power Company (SPPCo) in BLM application number CACA-31406. The BLM notice of availability of the draft EIR/S was published in the Federal Register on March 9, 1995 (60 FR 12967-12968), and provided a comment period on the draft EIR/S that ended May 3, 1995. This Amendment to the BLM notice of availability of a Draft EIR/S hereby extends the comment period until June 2, 1995. All comments on the Draft EIR/S for the Alturas 345 kilovolt (KV) transmission line project must be postmarked no later than June 2, 1995, and must be sent to: Julie Halligan/Peter Humm, CPUC/BLM; c/o Aspen Environmental Group; 30423 Canwood Street, Suite 218, Agoura Hills, CA 91301. For information call Peter Humm, BLM Project Manager, at (916) 257-0456.

Dated: April 27, 1995.

John Bosworth,

Acting District Manager.
[FR Doc. 95–11000 Filed 5–3–95; 8:45 am]
BILLING CODE 4310–40–M